GLSI
NASDAQ HealthcareGreenwich LifeSciences, Inc. - Common stock
Biotechnology
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
�� 市场数据
| 价格 | $27.74 |
|---|---|
| 成交量 | 229,386 |
| 市值 | 384.32M |
| 贝塔系数 | 1.530 |
| RSI（14日） | 68.9 |
| 200日均线 | $16.39 |
| 50日均线 | $25.76 |
| 52周最高 | $34.10 |
| 52周最低 | $7.78 |
| Forward P/E | -33.83 |
| Price / Book | 175.57 |
🎯 投资策略评分
GLSI 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (82/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🔪 Falling Knife (8/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 GLSI in your text
粘贴任何文章、记录或帖子 — 工具将提取 GLSI 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.